The US Food and Drug Administration approved the use of ivosidenib, an inhibitor of IDH1, to treat acute myelogenous leukemia (AML) harboring IDH1 mutations in a phase I clinical trial (23). This evidence concerns the gene IDH1 and acute myeloid leukemia.